Cargando…

Advances in metformin-based metabolic therapy for non-small cell lung cancer

Therapeutic approaches that target the metabolism of tumor cells have been a popular research topic in recent years. Previous studies have demonstrated that glycolysis inhibitors reduce the proliferation of non-small cell lung cancer (NSCLC) cells by interfering with the aerobic glycolytic pathway....

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Na, Zhou, Yi-Shu, Wang, Li-Cui, Huang, Jin-Bai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808708/ https://www.ncbi.nlm.nih.gov/pubmed/35039878 http://dx.doi.org/10.3892/or.2022.8266

Ejemplares similares

Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
por: Arrieta, Oscar, et al.
Publicado: (2016)

Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells
por: Ko, Eunjeong, et al.
Publicado: (2020)

Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis
por: Duan, Xueyu, et al.
Publicado: (2023)

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
por: Dong, Jingsi, et al.
Publicado: (2019)

Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum
por: Wen-Xiu, Xin, et al.
Publicado: (2018)

Prognostic value of metformin for non-small cell lung cancer patients with diabetes
por: Xu, Tongbai, et al.
Publicado: (2018)

Progress in the application and mechanism of metformin in treating non-small cell lung cancer
por: Li, Chan, et al.
Publicado: (2017)

Addition of metformin to non‐small‐cell lung cancer patients with or without diabetes
por: Chen, Hua‐Fen, et al.
Publicado: (2022)

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
por: Ma, Hong Yun, et al.
Publicado: (2023)

Targeted therapies for advanced non-small cell lung cancer
por: Ai, Xiaojuan, et al.
Publicado: (2018)

The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis
por: Liu, Ying, et al.
Publicado: (2014)

Metformin synergistic pemetrexed suppresses non‐small‐cell lung cancer cell proliferation and invasion in vitro
por: Zhang, Yan, et al.
Publicado: (2017)

Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
por: Wang, Haocheng, et al.
Publicado: (2020)

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
por: Wang, Yan, et al.
Publicado: (2023)

Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study
por: Jin, Yi-Hua, et al.
Publicado: (2019)

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2017)

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
por: Li, Shenduo, et al.
Publicado: (2023)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
por: Zhao, Dan, et al.
Publicado: (2017)

Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials
por: Troncone, Michael, et al.
Publicado: (2017)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
por: Majeed, Umair, et al.
Publicado: (2021)

Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model
por: Wang, Jiun-Long, et al.
Publicado: (2021)

Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice
por: Liang, Yi-Hsin, et al.
Publicado: (2016)

Recent advances of novel targeted therapy in non-small cell lung cancer
por: Katzel, Jed A, et al.
Publicado: (2009)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer
por: Wakelee, Heather, et al.
Publicado: (2018)

Long-term survival with targeted therapy in an advanced non-small cell lung cancer patient based on genetic profiling
por: Shen, Fang-Fang, et al.
Publicado: (2020)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Salvage surgery following downstaging of advanced non‐small cell lung cancer by targeted therapy
por: Li, Kuo, et al.
Publicado: (2021)

Recent advances in postoperative pulmonary rehabilitation of patients with non-small cell lung cancer (Review)
por: Su, Xue-E, et al.
Publicado: (2022)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018)

Effects of β-Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
por: Chaudhary, Kunal R., et al.
Publicado: (2019)

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells
por: Cao, Nini, et al.
Publicado: (2020)

Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
por: Ferdinandus, Justin, et al.
Publicado: (2021)

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
por: Wang, Jiun-Long, et al.
Publicado: (2021)

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer
por: Chen, Jin-Hua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9rr69b1pe7l8mgshndqjj2kgic